课题基金 / 基金详情

EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY MASS

EFFECT OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON LEAN BODY MASS
高活性抗逆转录病毒治疗对瘦体重的影响
批准号：
6291125
负责人：
JOSEPH WHEAT
金额：
$0.04万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6291125
关键词：
AIDS therapy antiviral agents appetite body composition clinical research clinical trials disease /disorder proneness /risk functional ability human immunodeficiency virus 1 human subject inflammation performance virus RNA

项目摘要

项目成果

JOSEPH WHEAT的其他基金

相似基金

相关文献

中文摘要
翻译
这是一项为期48周的观察性研究，对参与ACTG抗逆转录病毒研究的受试者进行高效抗逆转录病毒治疗(HAART)期间瘦体重、食欲、功能表现和全身炎症标志物的研究。这项研究将确定身体成分的变化是否与艾滋病毒-1RNA水平的变化有关，以及身体成分变化的幅度是否与艾滋病定义并发症的风险定量相关。这项研究没有任何减重或体重标准，只是受试者的体重必须低于或等于28公斤/平方米。
英文摘要
This is an observational 48-week study of lean body mass, appetite, functional performance, and systemic markers of inflammation during highly active antiretroviral therapy (HAART) in subjects co-enrolled in ACTG antiretroviral studies. The study will determine if changes in body composition are related to changes in HIV-1 RNA levels and whether the magnitude of these changes in body composition is quantitatively related to risks for AIDS-defining complications. There are no wasting or weight criteria for entry into this study except that subjects must be < or = to 28 kg/m2.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DAPSONE AND ATOVAQUONE FOR PROPHYLAXIS AGAINST PCP
THALIDOMIDE FOR TREATMENT OF ORAL/ESOPHAGEAL APHTHYOUS ULCERS AND HIV VIREMIA
AMBISOME VS AMPHOTERICIN B FOLLOWED BY FLUCONAZOLE IN TREATMENT OF MENINGITIS
CS96 209 SCH56592 VERSUS FLUCONAZOLE IN THE TREATMENT OF OROPHARYNGEAL CANDIDA
海外基金